Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Cytokinetics

BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization of aficamten in Japan.

Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan

Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular business with smaller deals.

Bayer acquires rights to Cytokinetics' heart drug in Japan

Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug development, to restore confidence and revive the company's share price that hit 20-year lows after its shock warning this week.

Bayer shareholders call on CEO to stem the tide of bad news

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDIA® (finerenone) in heart failure (HF) patients with a left ventricular ejection fraction (LVEF) of ≥40%, in a Featured Science session at the American Heart Association (AHA) Scientific Sessions 2024, taking place in Chicago, IL, from November 16-18, 2024. KERENDIA is currently approved to reduce the risk of cardio.

Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF ≥40% at AHA 2024

BAYRY's third-quarter earnings get affected due to impairment losses at the Crop Science division. Sales gain from the Pharmaceutical business's strong performance.

Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales

Bayer AG (OTCPK:BAYZF) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Bill Anderson - Chairman & CEO Wolfgang Nickl - CFO Julio Triana - President, Consumer Health Division Stefan Oelrich - President, Pharmaceuticals Division Rodrigo Santos - President, Crop Science Division Jost Reinhard - IR Conference Call Participants Vincent Andrews - Morgan Stanley Sachin Jain - Bank of America Joel Jackson - BMO James Quigley - Goldman Sachs Christian Faitz - Kepler Cheuvreux Richard Vosser - J.P. Morgan Laurent Favre - BNP Paribas Harry Sephton - UBS Sebastian Bray - Berenberg Thibault Boutherin - Morgan Stanley Steven Byrne - Bank of America Jost Reinhard Good afternoon, and good morning, everybody, and welcome to our conference call for the third quarter of 2024.

Bayer AG (BAYZF) Q3 2024 Earnings Call Transcript

Bayer faces significant risks from litigation and poor M&As, but its current low valuation presents a potential long-term upside, especially post-2025. Despite recent challenges and a dividend cut, Bayer's fundamentals remain solid, with potential for a 30% annual upside in the long term. Key segments like Consumer Health show promise, but Crop Science and Pharma face headwinds, including generic competition and muted market growth.

Bayer Stock: Assessing Upside Potential After Its Q3 Earnings

Bayer shares are falling 11% in German trading after the pharmaceuticals and crop science conglomerate reduced its full-year earnings target and warned of likely lower profit next year amid a tough agricultural market.

Bayer Stock Slumps on Outlook Cut

Bayer's stock slumped on Tuesday as the German giant gave a profit warning on agricultural demand.

Bayer's stock slumps after warning on crop-sciences unit

Bayer on Tuesday lowered its full-year operating earnings guidance, citing weaker agricultural markets in Latin America.

Bayer cuts FY operating earnings outlook on weak agriculture markets

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its MEDRAD® Centargo CT Injection System, an innovative multi-patient injector that drives workflow efficiency with design features that integrate with Bayer's portfolio of products, especially in high-volume CT suites. Bayer's MEDRAD® Centargo CT Injection System delivers value for radiology departments as the US faces a shortage of radiology technologists coupled with a.

Bayer's Receives FDA Clearance for MEDRAD® Centargo CT Injection System

BASEL, Switzerland--(BUSINESS WIRE)--Bayer has launched a first-of-its-kind in the healthcare industry, polyethylene terephthalate (PET) blister packaging on its renowned brand, Aleve. Realized in partnership with pharma packaging specialist Liveo Research, this innovative solution reduces the carbon footprint of this packaging by 38%1 and marks a stride in environmental stewardship by eliminating the use of polyvinyl chloride (PVC). Blister packaging, widely used in over-the-counter products,.

Bayer and Liveo Research Launch First-of-its-Kind Blister Packaging with Improved Environmental Footprint

BAYRY submits an application seeking EMA approval of elinzanetant for treating hot flashes associated with menopause or adjuvant endocrine therapy.

Bayer Seeks Approval for Elinzanetant for Vasomotor Symptoms in EU

Bayer on Tuesday said it had applied for marketing authorization with the European Medicines Agency (EMA) for its menopause relief drug elinzanetant.

Bayer submits EU marketing application for menopause relief drug

Bayer said on Monday that it has applied to the EU's drugs regulator for the use of Nubeqa, also known as darolutamide, in combination with androgen deprivation therapy.

Bayer applies for third indication of Nubeqa in EU

ORION CORPORATION INVESTOR NEWS 14 OCTOBER 2024 at 11.00 EEST          Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU Orion's collaboration partner Bayer today announced the submission of an application to the European Medicines Agency (EMA) for the oral androgen receptor inhibitor (ARi) darolutamide. Bayer is seeking approval for the use of darolutamide in combination with androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Orion's collaboration partner Bayer submits application for third indication of darolutamide in the EU

Bayer must pay $78 million to a Pennsylvania man who said he got cancer from using the company's Roundup weedkiller, a state court jury in Philadelphia found on Thursday.

Bayer must pay $78 mln in latest Roundup cancer trial, jury finds

German life sciences giant Bayer saw its shares drop by over 7% on Wednesday following a US court's decision to review a case against Monsanto, a subsidiary acquired by Bayer in 2018. The litigation involves claims that exposure to polychlorinated biphenyls (PCBs), used in Monsanto products, harmed students and staff at a Washington state school.

Bayer shares fall 7% as US court reconsiders Monsanto PCB exposure case

Washington state's top court granted a petition for review in a case over allegations of contamination against Bayer's Monsanto.

Bayer Shares Plunge After U.S. Legal Setback

Shares of German life sciences company Bayer fell more than 7% on Wednesday, after a U.S. court said it would review a case alleging that exposure products made by the company's Monsanto unit harmed individuals. The Washington Supreme Court this week accepted a review of a litigation against the German company over alleged polychlorinated biphenyls (PCBs) exposure at the Sky Valley Education Center.

Bayer shares down 7% after U.S. court says it will review Monsanto case

BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer and MOMA Therapeutics, Inc., a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced that they have entered into a collaboration, under an option and exclusive license agreement, to develop and commercialize a small molecule oncology program based on MOMA's proprietary KNOMATIC™ platform. Under the agreement, Bayer will be responsible for completing further preclinical, de.

Bayer and MOMA Therapeutics Enter Collaboration and License Agreement in Oncology

AstraZeneca

Eli Lilly

Pfizer

Sanofi

Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.

5 Large Drug Stocks to Watch From a Thriving Industry

BAYRY's experimental Parkinson's disease drug continues to show a favorable safety profile in all 12 participants in the trial's high and low-dose cohorts at 24 months.

Bayer Reports Positive Safety Data on Parkinson's Disease Drug

BAYRY moves ahead with the submission of an application seeking approval of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

News for Bayer AG Stock (BAYRY)